Opdivo Back On Par With Keytruda In Lung Cancer
This article was originally published in The Pink Sheet Daily
Though Merck’s Keytruda was recently approved for the full range of lung cancer patients, giving it a marketable advantage over the limited approval for Bristol's Opdivo in squamous disease, Bristol has caught up again with early FDA approval for the non-squamous population. FDA also added PD-L1 expression data to Opdivo’s label.
Register for our free email digests: